The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Vitamin D deficiency is now recognized as one of the most common vitamin deficiencies in adults in the United States. Vitamin D deficiency has been connected to many chronic health diseases. The goal of this innovative research is to identify how vitamin D is able to have such wide ranging health benefits. This study will determine which genes are turned on and turned off in adults who receive 2000 IU vitamin D3 per day compared to 400 IU vitamin D3 per day. Results should provide important new insights about the health benefits of vitamin D for adults.
| Condition | Intervention |
|---|---|
|
Vitamin D Deficiency |
Dietary Supplement: 400 IU vitamin D3 Dietary Supplement: 2000 IU vitamin D3 |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Effect of Vitamin D on Measures of Bone Health and Gene Expression |
- Gene Expression [ Time Frame: Baseline and Final Visits ] [ Designated as safety issue: No ]Measurement of mRNA levels from genes specific to bone, calcium, and non-skeletal functions.
Biospecimen Retention: Samples With DNA
Buffy coat has been retained from whole blood.
| Enrollment: | 11 |
| Study Start Date: | July 2009 |
| Study Completion Date: | June 2012 |
| Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Arm A
400 IU vitamin D3 once a day for 2 months
|
Dietary Supplement: 400 IU vitamin D3
Take 400 IU once/day for 2 months
|
|
Arm B
2000 IU Vitamin D3 once/day for 2 months
|
Dietary Supplement: 2000 IU vitamin D3
2000 IU vitamin D3 once/day for 2 months
|
Detailed Description:
Vitamin D, commonly known as the sunshine vitamin, is produced in the skin from sun exposure as well as from dietary sources. However, very few foods naturally contain vitamin D and the amount of vitamin D in fortified foods typically, 100 IU per serving, has been totally inadequate in satisfying adults vitamin D requirement, which is now been estimated to be at least 2,000 IU of vitamin D a day. As a result, vitamin D deficiency is rapidly being recognized world-wide as the most common vitamin deficiency. Upwards of 50-100% of children and adults have been reported as being vitamin D deficient depending on ethnicity, latitude and skin pigmentation. The investigators reported in women at the time of delivery that 76% of mothers and 81% of newborns were vitamin D deficient despite the fact that the mother was taking a prenatal vitamin containing 400 IU vitamin D and drinking two glasses of milk a day. The investigators also reported 30-80% vitamin D deficiency rates in white and black children, healthy young, middle aged and older adults. There have been numerous epidemiologic and clinical observations relating vitamin D deficiency to many chronic diseases and there are many isolated but no comprehensive studies evaluating various genes that are either suppressed or enhanced by 1,25-dihydroxyvitamin D [1,25(OH)2D]. It has been estimated that upwards of 2000 genes are directly or indirectly influence by 1,25(OH)2 D. To date, however, there have not been any genomic signatures identified in humans in response to correction of vitamin D deficiency. The goal of this pilot study is to determine whether or not vitamin D3 supplementation will affect biomarkers for calcium and bone metabolism, and how they alter gene expression biomarkers, especially genes related to the non-skeletal actions of vitamin D.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Healthy Students from Boston University Medical School
Inclusion Criteria:
- Male and female adults of all races ages 18 years and older
Exclusion Criteria:
1. Pregnant and lactating women.
2. Current or recent history of hepatic or renal disease
3. History of taking a daily supplement that contains more than 400 IU vitamin D2 or vitamin D3 within the past month or taking a pharmacologic amount of vitamin D2 or one of the active vitamin D analogs including Zemplar (Paricalcitol), Dovonex (calcipotriol), Hectorol (vitamin D pro hormone)
4. Subjects who are taking antiseizure medications or glucocorticoids.
5. Exposure to a tanning bed or tanning on a beach for more than eight hours within the past month.
6. Known history of elevated calcium. (> 10.5 mg% (mg/dl))
7. History of intestinal malabsorption (i.e. Cystic Fibrosis, Fat Malabsorption Syndrome, Crohn's Disease)
8. Unwilling to consent to this trial
Contacts and Locations More Information
No publications provided by Boston Medical Center
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Michael F. Holick, Dr. Michael Holick, Boston Medical Center |
| ClinicalTrials.gov Identifier: | NCT01696409 History of Changes |
| Other Study ID Numbers: | Vitamin D and Gene Expression |
| Study First Received: | June 25, 2012 |
| Last Updated: | October 1, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Vitamin D Deficiency Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Cholecalciferol Vitamin D |
Ergocalciferols Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on June 18, 2013